CompletedNCT00102479
Aripiprazole safety and how the body processes it in children and teens
About this title
Read the official source — NCT00102479Medication studyAges 10–17Schizophrenia
Understand this study
Who was this study for?
Listed age limits: 10 years to 17 years.
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: July 1, 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 21
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Not clearly listed
- Age range
- From 10 Years to 17 Years
- Official registry ID
- NCT00102479
- Official title
Show the full official title
A Phase II Study to Test PK Tolerability in Children and Adolescents
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Locations not listed
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole.
Who was this study for?
Listed age limits: 10 years to 17 years.
Want to explore more studies?
Explore studiesRelated studies
Fiber and Probiotics for Weight and Cognitive Changes With Schizophrenia or Bipolarity
A 26-week, International, Multicenter, Open-label Phase IIIb Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in ...